Pacira BioSciences Reports Full-Year and Fourth Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
Pacira Pharmaceuticals (PCRX) PT Raised to $67 at BMO Capital
February 28, 2022 8:49 AM ESTBMO Capital analyst Gary Nachman raised the price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $67.00 (from $62.00) while maintaining a Market Perform rating following results.
The analyst commented, "4Q beat although rev. was preannounced, but margin improvement coming through and should accelerate following... More
Pacira Pharma (PCRX) Tops Q4 EPS by 9c
February 24, 2022 8:04 AM ESTPacira Pharma (NASDAQ: PCRX) reported Q4 EPS of $0.99, $0.09 better than the analyst estimate of $0.90. Revenue for the quarter came in at $159.2 million versus the consensus estimate of $155.74 million.
GUIDANCE:
Today the company is providing full-year 2022 operating expense guidance as... More
